Research and Markets: Non-Hodgkin's Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/258e90/nonhodgkins_lymp) has announced the addition of GlobalData's new report "Non-Hodgkin's Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017" to their offering.

“Non-Hodgkin's Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017”

Non-Hodgkins Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.

The authors estimated the global Non-Hodgkins Lymphoma (NHL) market to be worth $6.5 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 7.74% annually over the next eight years to reach $11.9 billion by 2017. This growth can be primarily attributed to increased competition among the existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The NHL market growth will be further supported by the increased uptake of chemotherapy regimens, monoclonal antibodies and biologics. In 2009, Genentech Inc. (Roche), with its key drug Rituxan, was the leading player in the global NHL market. In 2009, Rituxan played a key role accounting to more than 80% share in the global NHL market. Pharmaceuticals and biopharmaceutical companies are under the way in reorganizing their NHL pipeline with combination therapies.

There are six approved drugs in 2008, and two new drugs were approved by FDA in the first quarter of 2009. NHL pipeline is strong with 264 drugs under different stages of clinical development. Drugs that are studied with Rituxan either belong to the new mechanism of action or to the existing/old mechanism of action. Combination therapies in clinical studies projected to be more efficacious and safer than monotherapies alone. In future, the NHL market is driven by combination therapies, monoclonal antibodies, biologics, and vaccines. GlobalData analyzed that the global NHL market is moderately served with current product options with significant scope available to new entrants that would capture value from underserved segments.

Key Topics Covered:

• 1.1 List of Tables
• 1.2 List of Figures
• 2 Non-Hodgkins Lymphoma Market: Introduction
• 3 Non-Hodgkins Lymphoma Market: Market Characterization
• 4 Non-Hodgkins Lymphoma Market: Competitive Assessment
• 5 Non-Hodgkins Lymphoma Market: Pipeline Assessment
• 6 Global Non-Hodgkins Lymphoma Market: Implications for Future Market Competition
• 7 Global Non-Hodgkins Lymphoma Market: Future Players in the Non-Hodgkins Lymphoma Market
• 8 Non-Hodgkins Lymphoma Market: Appendix

Companies Mentioned:

• Genentech, Inc. (Roche)
• GlaxoSmithKline plc. (GSK)
• Immunomedics, Inc.
• Seattle Genetics, Inc.
• Eli Lilly and Company
• Pfizer Inc. (Wyeth)
• Novartis
• Biogen Idec
• Genzyme Corporation

For more information visit http://www.researchandmarkets.com/research/258e90/nonhodgkins_lymp